JP2013532176A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013532176A5 JP2013532176A5 JP2013519027A JP2013519027A JP2013532176A5 JP 2013532176 A5 JP2013532176 A5 JP 2013532176A5 JP 2013519027 A JP2013519027 A JP 2013519027A JP 2013519027 A JP2013519027 A JP 2013519027A JP 2013532176 A5 JP2013532176 A5 JP 2013532176A5
- Authority
- JP
- Japan
- Prior art keywords
- fviii variant
- recombinant fviii
- amino acid
- recombinant
- variant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 102100026735 Coagulation factor VIII Human genes 0.000 claims 21
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 claims 21
- 238000000338 in vitro Methods 0.000 claims 4
- 238000006467 substitution reaction Methods 0.000 claims 4
- 125000003275 alpha amino acid group Chemical group 0.000 claims 3
- 125000000539 amino acid group Chemical group 0.000 claims 3
- 230000002209 hydrophobic effect Effects 0.000 claims 3
- 238000003776 cleavage reaction Methods 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 230000007017 scission Effects 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 201000003542 Factor VIII deficiency Diseases 0.000 claims 1
- 208000009292 Hemophilia A Diseases 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 229940053200 antiepileptics fatty acid derivative Drugs 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 235000014113 dietary fatty acids Nutrition 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 230000009881 electrostatic interaction Effects 0.000 claims 1
- 229930195729 fatty acid Natural products 0.000 claims 1
- 239000000194 fatty acid Substances 0.000 claims 1
- 150000004665 fatty acids Chemical class 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 150000004676 glycans Chemical class 0.000 claims 1
- 229920001477 hydrophilic polymer Polymers 0.000 claims 1
- 230000003993 interaction Effects 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10169592.2 | 2010-07-15 | ||
| EP10169592 | 2010-07-15 | ||
| US36547810P | 2010-07-19 | 2010-07-19 | |
| US61/365,478 | 2010-07-19 | ||
| PCT/EP2011/061349 WO2012007324A2 (en) | 2010-07-15 | 2011-07-06 | Stabilized factor viii variants |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013532176A JP2013532176A (ja) | 2013-08-15 |
| JP2013532176A5 true JP2013532176A5 (https=) | 2014-08-21 |
Family
ID=42797590
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013519027A Ceased JP2013532176A (ja) | 2010-07-15 | 2011-07-06 | 安定化させた第ｖｉｉｉ因子バリアント |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US20130183280A1 (https=) |
| EP (1) | EP2593130A2 (https=) |
| JP (1) | JP2013532176A (https=) |
| CN (1) | CN102971006A (https=) |
| WO (1) | WO2012007324A2 (https=) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7855279B2 (en) | 2005-09-27 | 2010-12-21 | Amunix Operating, Inc. | Unstructured recombinant polymers and uses thereof |
| ES2610356T3 (es) | 2009-02-03 | 2017-04-27 | Amunix Operating Inc. | Polipéptidos recombinantes extendidos y composiciones que comprenden los mismos |
| CA2771999A1 (en) | 2009-08-24 | 2011-03-10 | Amunix Operating Inc. | Coagulation factor vii compositions and methods of making and using same |
| US20130017997A1 (en) * | 2010-08-19 | 2013-01-17 | Amunix Operating Inc. | Factor VIII Compositions and Methods of Making and Using Same |
| DK3424953T3 (en) * | 2011-06-06 | 2020-11-02 | Novo Nordisk As | Terapeutiske antistoffer |
| JP6256882B2 (ja) * | 2012-02-15 | 2018-01-10 | アムニクス オペレーティング インコーポレイテッド | 第ｖｉｉｉ因子組成物、ならびに組成物の作製方法および用途 |
| EP2822577B1 (en) | 2012-02-15 | 2019-02-06 | Bioverativ Therapeutics Inc. | Recombinant factor viii proteins |
| WO2013160005A1 (en) * | 2012-04-24 | 2013-10-31 | Novo Nordisk A/S | Pharmaceutical composition suitable for treatment of haemophilia |
| CN104661685A (zh) | 2012-10-15 | 2015-05-27 | 诺和诺德保健Ag（股份有限公司） | 因子vii缀合物 |
| UY35343A (es) * | 2013-02-26 | 2014-09-30 | Bayer Healthcare Llc | Formulaciones y procedimientos para la producción de proteína recombinante aumentada |
| LT3013855T (lt) | 2013-06-24 | 2021-01-25 | Xiao, Weidong | Mutavusio viii faktoriaus kompozicijos ir metodai |
| TW202003554A (zh) | 2013-08-14 | 2020-01-16 | 美商百歐維拉提夫治療公司 | 因子ｖｉｉｉ－ｘｔｅｎ融合物及其用途 |
| CA2927756A1 (en) | 2013-10-15 | 2015-04-23 | Novo Nordisk Health Care Ag | Coagulation factor vii polypeptides |
| US20160252519A1 (en) * | 2013-10-18 | 2016-09-01 | Dr. Reddy's Laboratories Limited | In-vitro method for determining fate of polypeptide variant |
| WO2015132724A1 (en) | 2014-03-05 | 2015-09-11 | Pfizer Inc. | Improved muteins of clotting factor viii |
| CN106687126B (zh) | 2014-08-04 | 2020-07-28 | 杰特有限公司 | 因子viii制剂 |
| ES2772933T3 (es) | 2015-03-06 | 2020-07-08 | CSL Behring Lengnau AG | Factor de von Willebrand modificado que tiene una semivida mejorada |
| EA201890423A1 (ru) | 2015-08-03 | 2018-07-31 | Биовератив Терапьютикс Инк. | Слитые белки фактора ix, способы их получения и применения |
| MX2019006444A (es) | 2016-12-02 | 2019-10-30 | Bioverativ Therapeutics Inc | Métodos de tratamiento de artropatía hemofílica utilizando factores de coagulación quiméricos. |
| PL3793588T3 (pl) | 2018-05-18 | 2025-09-01 | Bioverativ Therapeutics Inc. | Sposoby leczenia hemofilii a |
| WO2021001522A1 (en) | 2019-07-04 | 2021-01-07 | CSL Behring Lengnau AG | A truncated von willebrand factor (vwf) for increasing the in vitro stability of coagulation factor viii |
| CN114929735A (zh) * | 2019-11-01 | 2022-08-19 | 自由行疗法有限公司 | 因子viii构建体 |
| US20220348637A1 (en) | 2019-11-11 | 2022-11-03 | CSL Behring Lengnau AG | Polypeptides for inducing tolerance to factor viii |
| CN116669755A (zh) * | 2020-09-23 | 2023-08-29 | 艾柏力维亚生技有限公司 | 用于增加因子viii替代疗法的效力的化合物 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2645588A (en) | 1987-12-04 | 1989-06-15 | Scripps Clinic And Research Foundation | The von willebrand factor binding domain of factor viii |
| US5824784A (en) | 1994-10-12 | 1998-10-20 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
| EE05214B1 (et) | 1998-04-28 | 2009-10-15 | Applied Research Systems ARS Holding N.V. | Polool-IFN- β konjugaat, selle valmistamismeetod ja farmatseutiline kompositsioon |
| ES2331909T3 (es) * | 2001-06-14 | 2010-01-20 | The Scripps Research Institute | Factor viii estabilizado con enlaces disulfuro modificados geneticamente. |
| ES2411007T3 (es) | 2001-10-10 | 2013-07-04 | Novo Nordisk A/S | Remodelación y glicoconjugación de péptidos |
| US20100143969A1 (en) | 2005-03-24 | 2010-06-10 | Neose Technologies, Inc. | Expression of soluble, active eukaryotic glycosyltransferases in prokaryotic organisms |
| EP1871801A2 (en) * | 2005-04-01 | 2008-01-02 | Novo Nordisk Health Care AG | Blood coagulation fviii analogues |
| US20090041744A1 (en) * | 2005-06-17 | 2009-02-12 | Novo Nordisk Healthcare A/G | Dimeric and Multimeric FVIIa Compounds |
| ES2553160T3 (es) * | 2005-06-17 | 2015-12-04 | Novo Nordisk Health Care Ag | Reducción y derivatización selectivas de proteínas Factor VII transformadas por ingeniería que comprenden al menos una cisteína no nativa |
| WO2007056191A2 (en) | 2005-11-03 | 2007-05-18 | Neose Technologies, Inc. | Nucleotide sugar purification using membranes |
| AU2007245190B2 (en) * | 2006-03-31 | 2011-07-21 | Takeda Pharmaceutical Company Limited | Pegylated factor VIII |
| EP2049144B8 (en) * | 2006-07-21 | 2015-02-18 | ratiopharm GmbH | Glycosylation of peptides via o-linked glycosylation sequences |
| PL2257311T3 (pl) | 2008-02-27 | 2014-09-30 | Novo Nordisk As | Koniugaty cząsteczek czynnika VIII |
| US20100099616A1 (en) * | 2008-10-17 | 2010-04-22 | Baxter International Inc. | Modified blood factors comprising a low degree of water soluble polymer |
-
2011
- 2011-07-06 JP JP2013519027A patent/JP2013532176A/ja not_active Ceased
- 2011-07-06 EP EP11735405.0A patent/EP2593130A2/en not_active Withdrawn
- 2011-07-06 CN CN2011800348298A patent/CN102971006A/zh not_active Withdrawn
- 2011-07-06 WO PCT/EP2011/061349 patent/WO2012007324A2/en not_active Ceased
- 2011-07-06 US US13/808,204 patent/US20130183280A1/en not_active Abandoned
-
2016
- 2016-06-01 US US15/170,502 patent/US20160264645A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013532176A5 (https=) | ||
| Tan et al. | Functionalization of graphene oxide generates a unique interface for selective serum protein interactions | |
| ES2563646T3 (es) | Composiciones y métodos relacionados con variantes de la proteína A (SpA) | |
| PE20170071A1 (es) | Moleculas de anticuerpo que se unen a lag-3 y usos de las mismas | |
| AR119682A2 (es) | Composiciones inmunogénicas de antígenos de staphylococcus aureus | |
| RU2019124678A (ru) | Слитый белок pd1-41bbl и способы его применения | |
| CR11561A (es) | Proteinas de union a antigenos | |
| BR112019011988A2 (pt) | anticorpo anti-cd73 humana | |
| EA201400568A1 (ru) | Альбуминсвязывающие антитела и их связывающие фрагменты | |
| PE20230404A1 (es) | Un conjugado que comprende oxintomodulina y un fragmento de inmunoglobulina, y uso del mismo | |
| MA37983A1 (fr) | Analogues du glucagon | |
| PE20190911A1 (es) | Composiciones y anticuerpos anti-lag-3 | |
| HRP20220214T1 (hr) | Imunomodulacijska sredstva | |
| JP2018505146A5 (https=) | ||
| IN2012DN03368A (https=) | ||
| AR094141A1 (es) | Composiciones y metodos para proteinas de accion prolongada | |
| MX341921B (es) | Proteinas de union a antigeno. | |
| NZ705384A (en) | Composition for treating hyperlipidemia comprising oxyntomodulin derivative | |
| EA202190264A1 (ru) | КОМПОЗИЦИИ АНТИТЕЛ ПРОТИВ FcRn | |
| IN2014KN01716A (https=) | ||
| WO2011036443A3 (en) | Si protease c- terminal polypeptides and uses thereof for treating inflammation or coagulation disorders | |
| ES2675847T3 (es) | Nuevo anticuerpo anti-DR5 | |
| JP2012115277A5 (https=) | ||
| WO2012018767A3 (en) | Antibodies directed against il-17 | |
| CL2012000715A1 (es) | Compuesto agonista del receptor de peptido natriuretico b (npr-b), que comprende peptidos lineales que contienen 9 residuos aminoacidicos; y su uso para preparar un medicamento para disminuir la presion intraocular. |